Literature DB >> 31128291

Neuregulin 1 Fusion-Positive NSCLC.

Misako Nagasaka1, Sai-Hong Ignatius Ou2.   

Abstract

Entities:  

Year:  2019        PMID： 31128291     DOI： 10.1016/j.jtho.2019.05.015

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  8 in total

Review 1.  New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).

Authors:  Alessandro Russo; Ana Rita Lopes; Michael G McCusker; Sandra Gimenez Garrigues; Giuseppina R Ricciardi; Katherine E Arensmeyer; Katherine A Scilla; Ranee Mehra; Christian Rolfo
Journal:  Curr Oncol Rep       Date:  2020-04-16       Impact factor: 5.075

2.  A Performance Comparison of Commonly Used Assays to Detect RET Fusions.

Authors:  Soo-Ryum Yang; Umut Aypar; Ezra Y Rosen; Douglas A Mata; Ryma Benayed; Kerry Mullaney; Gowtham Jayakumaran; Yanming Zhang; Denise Frosina; Alexander Drilon; Marc Ladanyi; Achim A Jungbluth; Natasha Rekhtman; Jaclyn F Hechtman
Journal:  Clin Cancer Res       Date:  2020-12-03       Impact factor: 12.531

Review 3.  Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy.

Authors:  Kenichi Suda; Tetsuya Mitsudomi
Journal:  Transl Lung Cancer Res       Date:  2020-12

4.  NRG1 fusions in breast cancer.

Authors:  Karen D Howarth; Tashfina Mirza; Susanna L Cooke; Suet-Feung Chin; Jessica C Pole; Ernest Turro; Matthew D Eldridge; Raquel Manzano Garcia; Oscar M Rueda; Chris Boursnell; Jean E Abraham; Carlos Caldas; Paul A W Edwards
Journal:  Breast Cancer Res       Date:  2021-01-07       Impact factor: 6.466

5.  Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing.

Authors:  Sai-Hong Ignatius Ou; Joanne Xiu; Misako Nagasaka; Bing Xia; Shannon S Zhang; Qing Zhang; Jeffrey J Swensen; David Spetzler; Wolfgang Michael Korn; Viola W Zhu; Stephen V Liu
Journal:  JTO Clin Res Rep       Date:  2020-12-24

Review 6.  Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies.

Authors:  Anthony Turpin; Cindy Neuzillet; Elise Colle; Nelson Dusetti; Rémy Nicolle; Jérôme Cros; Louis de Mestier; Jean-Baptiste Bachet; Pascal Hammel
Journal:  Ther Adv Med Oncol       Date:  2022-09-06       Impact factor: 5.485

7.  Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.

Authors:  Alexander Drilon; Michael Duruisseaux; Ji-Youn Han; Masaoki Ito; Christina Falcon; Soo-Ryum Yang; Yonina R Murciano-Goroff; Haiquan Chen; Morihito Okada; Miguel Angel Molina; Marie Wislez; Philippe Brun; Clarisse Dupont; Eva Branden; Giulio Rossi; Alexa Schrock; Siraj Ali; Valérie Gounant; Fanny Magne; Torsten Gerriet Blum; Alison M Schram; Isabelle Monnet; Jin-Yuan Shih; Joshua Sabari; Maurice Pérol; Viola W Zhu; Misako Nagasaka; Robert Doebele; D Ross Camidge; Maria Arcila; Sai-Hong Ignatius Ou; Denis Moro-Sibilot; Rafael Rosell; Lucia Anna Muscarella; Stephen V Liu; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2021-06-02       Impact factor: 50.717

Review 8.  Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers.

Authors:  Aaron C Tan; Malinda Itchins; Mustafa Khasraw
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.